What are the opening hours?

Monday 8am - 4pm Tuesday 8am - 4pm Wednesday 8am - 4pm Thursday 8am - 4pm Friday 8am - 2pm

http://www.a-atlantichearing.com/

A Atlantic Hearing Aid Center, 2310 E Oakland Park Boulevard, Fort Lauderdale, FL (2025)

04/24/2023

Masonic Charity Foundation grant funds, Oklahoma School for the Deaf, senior citizens' hearing aids program

The Masonic Charity Foundation of Oklahoma’s has awarded a $125,000 grant to purchase hearing aids through the statewide Senior Citizens Hearing Aid Program operated by the Oklahoma School for the Deaf.

Since 2018, the Masonic Foundation has donated four times to clear waiting lists and help lower-income seniors get hearing aids through the OSD program.

A new study by Johns Hopkins Bloomberg School of Public Health found that seniors with hearing loss have a greater chance of developing dementia, but dementia prevalence is lower among hearing aid users compared to non-users.

“When older Oklahoma start to lose their hearing, many can’t afford to purchase hearing aids,” John Logan, Masonic Charity Foundation executive director said. “Our board is proud to make a significant grant to help them because we know this outstanding program runs out of money every year.

“We appreciate the detailed information OSD gives us showing how funds are used and their map of services which indicates only two counties in Oklahoma were not served by this program last year,” Logan added.

When Masonic Charity Foundation President Neil Stitt and Grand Master Glen A. Chaney presented the grant, Sarah Jameson, OSD administrative coordinator, said, “Your donation enables OSD to not have a waiting list so we’re able to serve for an entire year,”

Jameson supervises OSD’s Equipment Distribution Program, which includes the Senior Citizens Hearing Aid Program.

“Because of the Mason’s donation, seniors served by this program are able to meet with their friends, have lunch, have conversations with their grandchildren, their husbands, their wives – just conversations that they haven’t been a part of for a long time,“ Renate Neal, equipment distribution program coordinator, explained.

OSD’s hearing aid program is funded by a 5-cent fee on telephone service for those who have conventional metal wire or optical fiber telephone connections, known as land lines.

“Regular funding for the program has declined because many Oklahomans have switched to cell phones, which do not currently pay the telephone service fee,” OSD Superintendent Dr. Heather Laine said. “We could help more people if this small fee applied to cell phones and mobile devices.”

To qualify for the Senior Citizens Hearing Aid Program, Oklahoma residents must be 60 years of age, with limited income and a 35-decibel hearing loss in their better ear.

The program pays for an audiology examination, ear mold impression, hearing aid fitting and one non-digital hearing aid per person due to limited funding and the need to serve as many seniors as possible.

OSD contracts with audiologists across the state so seniors can be served as near as possible to their homes.

Individuals can only receive two hearing aids if they are deaf and blind, or if they have waited five years after receiving their first hearing aid through the program.

OSD is a division of the Oklahoma Department of Rehabilitation Services.

For more information about the program, phone 866-309-1717, video phone 405-294-3977 or visit http://www.osd.k12.ok.us/edp/senior_hearing_aid.pdf.

Source: Jody Harlan | Special to The Ada News

Image Credit: Masonic Charity Foundation of Oklahoma President Neil Stitt (left) and Grand Master Glen A. Chaney (right) present a donation to Oklahoma School for the Deaf to purchase hundreds of hearing aids for low-income senior citizens: (2nd from left) Renate Neal, equipment distribution program coordinator; Sarah Jameson, OSD administrative coordinator; and Dr. Heather Laine, OSD superintendent.

04/21/2023

Is there an association between hearing aid use and risk of dementia?

In a recent study published in The Lancet Public Health Journal, the researchers examined the correlation between the use of hearing aids and the risk of developing dementia.

Background:
Both hearing loss and dementia are common in older adults. Using hearing aids to treat hearing loss in middle-aged or older individuals could potentially lower the risk of dementia.

The impact of hearing aid use on reducing the risk of dementia in real-world situations is uncertain, despite studies indicating that it can enhance cognitive function and reduce cognitive decline.

About the study:
In the present study, researchers investigated the link between hearing aid usage and the likelihood of developing cause-specific and all-cause dementia.

UK Biobank is a cohort study that enrolled more than 500,000 volunteers aged between 40 years and 69 years from 2006 to 2010. A questionnaire was used to gather data on hearing loss and hearing aid usage.

The participant's hearing status was determined through a self-reported question that asked, "Do you experience any hearing difficulties?" Users can respond with "no", "yes", or "I am completely deaf".

The hearing loss status was divided into two categories: those without hearing loss and those with hearing loss. The study gathered information on the usage of hearing aids through a self-reported question that asked participants if they used a hearing aid often, with the option to answer "yes" or "no".

Starting in 2009, UK Biobank participants were surveyed about their use of hearing aids. Deaf participants were categorized as part of the group including individuals with hearing loss who did not use hearing aids, without being questioned about their use of hearing aids.

Dementia diagnoses were determined through hospital inpatient records as well as death register data. The study measured incident all-cause dementia as the outcome variable, which included subtypes such as Alzheimer's disease, non-Alzheimer's disease, nonvascular dementia, and vascular dementia.

Results:
Almost 437,704 individuals were included in the analyses. The study involved participants with a mean age of 56.0 years, consisting of 235,249 females and 202,455 males at baseline. The average length of follow-up was 12.1 years.

There were 325,882 participants without hearing loss and 111,822 with hearing loss. Approximately 13,092 individuals with hearing loss utilized hearing aids.

Hearing loss was more prevalent in men than women and increased with age. Individuals who suffer from obesity, loneliness, depressed mood, and cardiovascular disease are more likely to experience hearing loss and use hearing aids.

Individuals who had hearing loss but did not use hearing aids have a higher likelihood of developing all-cause dementia in comparison to those without hearing loss while people with hearing loss using hearing aids did not report increased risk.

The proportion of dementia risk among people with hearing loss who did not use hearing aids was almost 29%. Similar findings were observed for correlations with dementia subtypes. The study found that there were no significant differences between men and women in the results of stratified analyses.

However, the attributable risk proportions for different dementia types for hearing loss without using a hearing aid were higher among females than in males.

The study found that mediators played a role in the relationship between dementia and hearing aid usage. Specifically, 1.52% of the association was attributed to improved social isolation, 2.28% to improved loneliness, and 7.14% to improved depressed mood.

Significant interactions were observed for dementia, education, smoking, income level, cardiovascular disease, and APOE e4 allele status. Furthermore, dementia was found to be more prevalent in high-risk groups.

Individuals with hearing loss who did not use hearing aids had the highest risk across most interaction variables, while those who used hearing aids had lower to no risk increases compared to individuals having no hearing loss.

Two APOE e4 alleles were linked to higher dementia risk and did not show significant risk variations across hearing loss and hearing aid usage.

Conclusion:

The study findings showed that individuals with hearing loss have a 42% higher risk of developing dementia compared to those with normal hearing. Up to 8% of dementia cases could be prevented with hearing loss management, highlighting the important need to address this issue.

Using hearing aids was linked to a similar risk of dementia as individuals without hearing loss. Further highlighting a need to better our hearing loss management.

Associations were found in cause-specific and all-cause dementia subtypes. Clinical trials are necessary to evaluate the impact of hearing aid usage on dementia risk.

The role of various types of hearing aids and the duration of their use in preventing dementia in hearing impairment also needs to be determined.

Source: Bhavana KunkalikarApr, News Medical Net
Journal reference:
Jiang, F., Mishra, S.R., Shrestha, N., Ozaki, A., Virani, S.S., Bright, T., Kuper, H., Zhou, C. and Zhu, D., 2023. Association between hearing aid use and all-cause and cause-specific dementia: an analysis of the UK Biobank cohort. The Lancet Public Health. doi: 10.1016/S2468-2667(23)00048-8 https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(23)00048-8/fulltext

Image Credit: Dreamstime

04/20/2023

Announcing the Third Annual Good Vibrations Day - Bone Anchored Awareness Day

Oticon Medical will once again celebrate Good Vibrations Day on May 3, 2023. This marks the third year since the company founded this non-branded celebration to raise awareness of bone conduction hearing treatment, which is also known as Bone Anchored Awareness Day. By opening the celebration to all bone conduction device manufacturers, audiology professionals, and wearers, the hope is that more people who could benefit from this hearing solution will learn about its benefits worldwide.

May 3 was selected specifically because it is the birthday of Per-Ingvar Brånemark, a Swedish physician and research professor known as the father of osseointegration, and the godfather of bone anchored hearing. His discoveries enabled the development of modern bone conduction hearing devices.

Wearers first joined the celebration of Good Vibrations Day in 2021 by sharing video clips, photos, and stories depicting their lives with a bone anchored hearing system. They have continued to share their experiences with others year-round, helping to spread the word about bone conduction as an effective treatment for certain forms of hearing loss.

“For over 10 years I lived unaided and was miserable,” said wearer Ross W. “I would often sit with others and just smile because I was lost by the conversations going on around me. I never could tell what anyone was saying, so it created a disconnect. But when I got my first bone anchored hearing system, I was out in the open talking to everyone rather than in a corner. I was also smiling a lot because I was engaged. It changed everything!”

Bone conduction describes having sound vibrations conducted into the cochlea via the skull. Bone anchored hearing systems use this process, bypassing missing or damaged portions of the wearer’s outer or middle ear and sending vibrations via the skull directly into the inner ear. From there, they can be processed by the brain as sound.

Currently, more than 250,000 people from all over the world use some form of a bone conduction hearing device. Good Vibrations Day celebrates them and their treatment—regardless of brand—by providing an opportunity and encouragement to share their experiences with this life-changing hearing technology.

“Oticon Medical knows that sound matters,” said René Govaerts, General Manager at Oticon Medical. “We launched Good Vibrations Day in 2021 and have continued to celebrate it annually because it is an important way to raise awareness about the benefits of bone conduction. Many people around the world still don’t know that bone anchored hearing systems are options for addressing their conductive or single-sided hearing losses. We will proudly continue to do whatever we can, in partnership with other manufacturers, hearing healthcare professionals, and current wearers, to spread the word about this effective treatment option.”

Leading up to and including May 3, Oticon Medical will be celebrating Good Vibrations Day around the world by sharing information, videos and photos from wearers, holding contests, and more through its social media platforms. As a non-branded awareness day, the company invites other bone anchored brands to join in the celebration by sharing content and organizing celebrations of their own.

Good Vibrations Day posts, stories, tweets, reels, etc. can be shared by all using the and hashtags. They can also be viewed and shared via the official Good Vibrations Day page: www.facebook.com/boneanchoredhearing. Hearing healthcare professionals and wearers alike are encouraged to join the Good Vibrations Day page.

About Oticon Medical

All our passion, knowledge, technology, and global resources are aimed at supporting professionals and helping users overcome their hearing loss so they can live full lives – now and in the future. Because we know how much sound matters.

Source: Oticon Medical
image credit: Oticon Medical

04/19/2023

Scientists Create Drug-like Cocktail to Regenerate Hair Cells

Researchers make breakthrough with drug-like cocktail to regenerate hair cells using a mouse model.

Experts say that effective hearing loss treatments have eluded medicine due to sensory cells in the inner ear—called hair cells—becoming damaged or destroyed, of which cannot be regenerated. This loss of hair cells, which can be caused by aging, noise exposure, and other factors, renders an individual’s hearing loss permanent.

Scientists at Mass Eye and Ear, a member of Mass General Brigham, share that they may have developed a solution to address this limitation. A research team led by Zheng-Yi Chen, DPhil, an associate scientist in the Eaton-Peabody Laboratories at Mass Eye and Ear, reports that they have created a drug-like cocktail of different molecules that successfully regenerated hair cells in a mouse model by reprogramming a series of genetic pathways within the inner ear.

The researchers published their findings April 17 in Proceedings of the National Academy of Sciences (PNAS), stating that they could one day pave the way for clinical trials for a gene therapy that can be administered to people with hearing loss.

“These findings are extremely exciting because throughout the history of the hearing loss field, the ability to regenerate hair cells in an inner ear has been the holy grail,” commented Chen, who is also an associate professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School. “We now have a drug-like cocktail that shows the feasibility of an approach that we can explore for future clinical applications.”

Past research notes that hearing loss impacts about 48 million Americans and 430 million people worldwide, with the numbers expected to grow with the aging population. More than 90% of these individuals have sensorineural hearing loss, which is reportedly caused by damage to the inner ear and the destruction of hair cells responsible for relaying sounds to the brain. Preceding research states that hair cells cannot be regenerated in mammals, including humans, because unlike other cells in the body, any remaining hair cells in the inner ear cannot divide and other inner ear cells cannot convert themselves into new hair cells. Other species like fish, birds and reptiles, however, possess this ability.

Previously, it has been reported that Chen’s research team studied zebrafish and chickens to uncover which pathways were responsible for inducing the cell division required to regenerate new hair cells. They discovered two molecular signaling pathways—Myc and Notch—were crucial to this process. In a study published in 2019, they demonstrated that when these pathways were activated in adult transgenic mice, remaining inner ear cells could divide and develop characteristics of hair cells. According to the team, the new cells contained transduction channels that relay sound signals and the ability to form connections with auditory neurons—processes essential to hearing.

According to Chen, while an exciting discovery at the time, such an approach was not directly translatable to people. Unlike transgenic mice, humans cannot have Myc and Notch pathways turned on like a light switch. A drug therapy, he explained, would have to be introduced to the inner ear to activate the Myc and Notch pathways.

Previous studies have shown that a chemical compound called valproic acid (VPA), can activate Notch, however, as of now no molecule exists to effectively activate Myc. That led the researchers to instead look for drug molecules that can alter the downstream pathways that turn on and off when Myc is activated. Through single-cell RNA sequencing, they discovered that activating Myc and Notch led to a downstream effect in which two other pathways, Wnt and cAMP, became activated. The researchers noted they found chemical compounds that can directly activate Wnt and cAMP, which were said to be of utmost importance. They then used small biological molecules called small interfering RNAs (siRNA) to remove genes downstream that suppressed the activation of the Myc pathway.

“Think about a brake when driving a car,” explained Chen. “If the brake is always engaged, you can’t drive. We found an siRNA that could remove the brake in this genetic pathway.”

The researchers then combined the chemical compounds and siRNA molecules into a drug-like cocktail. They delivered it to the inner ear of a normal adult mouse with damaged hair cells—an important distinction, as wildtype, non-transgenic mice would be more translatable to humans. They further delivered the gene Atoh1 by a gene therapy approach that utilizes a harmless adenovirus into the cocktail-treated inner ear. Remarkably, they found this drug-like cocktail combined with adenovirus turned on Myc and Notch, which led to the regeneration of new hair cells. They verified that the hair cells were functional through advanced imaging and other techniques.

Last year, this research project was selected as one of the “Disruptive Dozen” gene and cell therapy technologies most likely to have a significant impact on health care over the next several years at the Mass General Brigham World Medical Innovation Forum. Mass General Brigham recently launched its Gene and Cell Therapy Institute to help translate scientific discoveries made by researchers like Chen into first-in-human clinical trials.

It has been reported that the researchers are conducting ongoing studies and refinements to this treatment approach in larger animal models, which they say are necessary before applying to initiate clinical trials. They note that more research is needed to address limitations and challenges for delivering a treatment to the inner ear. They are examining different gene therapy and surgical methods, including an approach previously honed at Mass Eye and Ear, in which a different viral vector called an adeno-associated virus (AAV) was able to precisely and safely deliver gene therapy to the inner ear through a novel surgery. Similar AAV-surgical approaches are currently used at Mass Eye and Ear in approved and experimental drug therapies for patients with blinding inherited retinal disorders.

“My colleagues and I frequently are contacted by people with hearing loss who are desperate for effective treatments,” commented Chen. “If we can combine a surgical procedure with a refined gene therapy delivery method, we hope we can achieve our number one goal of bringing a new treatment into the clinic.”

Source: Mass Eye and Ear
Images: Dreamstime

04/18/2023

Rexton Adds Four Devices to Portfolio

Hearing aid manufacturer, Rexton, announces the launch of the newest additions to their BiCore portfolio: BiCore B-Li M Rugged, BiCore BTE M, BiCore BTE P, and BiCore BTE HP—all behind-the-ear (BTE) hearing aids.

According to Rexton product manager, Katie Stocker, the new BiCore B-Li M Rugged is intended for full-time patient use, matching the company’s audio quality with durability enhancements, and a smaller, more discrete size.

“The best hearing aids are ones patients can forget they’re wearing, and the BiCore B-Li M Rugged does just that while featuring dependable audio and a robust Lifeproof design that can withstand the drops, splashes and scratches of everyday life,” commented Stocker. “By reducing the device’s size and increasing its resiliency to the elements, BiCore B-Li M Rugged enables a more carefree patient experience free of interruptions, with long-lasting battery life of up to 39 hours, advanced binaural sound processing and simple audio streaming with iOS and Android devices, ensuring reliable performance in every situation.”

According to the company, the BiCore B-Li M Rugged offers enhanced resistance to water, soap, drops, scratches and even sweat.

“Our new BiCore B-Li M Rugged empowers hearing care professionals (HCPs) to offer patients enhanced device reliability and performance that can significantly impact daily activities, all while reducing the likelihood of damage and subsequent repair or replacement costs,” added Mike O’Neil, President of Rexton. “It’s a win-win that enables improved patient outcomes and reduces the need for HCPs to invest time and money managing device-related issues. With BiCore B-Li M Rugged, HCPs can focus on helping patients attain greater freedom and peace of mind through consistently improved hearing experiences, no matter what the day brings.”

According to the company, the other newly released hearing aid products—BiCore BTE M, BiCore BTE P and BiCore BTE HP—are battery-operated hearing aids that feature direct audio streaming with iOS and Android devices (Performance Levels 30 and 20), IP68 protection against dust, sand, dirt, submersion in over a meter of water, and an integrated telecoil.

All four hearing aids are reportedly built on Rexton’s BiCore platform, an advanced binaural platform that company leaders say optimizes synchronization between left and right hearing aids to provide clarity and natural sound experiences. The BiCore platform also includes Rexton’s patented Speech Preservation Technology that removes unwanted noise and emphasizes speech for clearer conversations in all environments.

“The BiCore platform is ideal for patients who consistently experience drastic changes in noise levels, such as on construction sites, first responder situations and busy school environments,” O’Neil said. “The platform and all the models built on it are specifically engineered to adapt quickly to significant soundscape changes, delivering a solution that patients can count on to help them live and work as effectively, efficiently, and dependably as possible.”

Source: Rexton
Image credit: Rexton

04/17/2023

Starkey CEO Named Executive of the Year

Starkey President and CEO Brandon Sawalich is named Executive of the Year in the 2023 Excellence in Customer Service Awards. The recognition is presented by Business Intelligence Group and recognizes those who are helping companies better communicate with their customers to provide a differentiated level of customer service.

“Starkey’s mission is to serve our customers better than anyone else, but there’s a much deeper meaning to that seemingly simple statement,” explained Sawalich. “Our customers are our partners in helping people around the world hear better, so they can live better lives. Our hearing technology provides the best sound quality, but without our customers, it wouldn’t reach the ears of patients who need it most. I am grateful our partners in better hearing continue to put their trust in Starkey.”

Sawalich started working at the company when he was 19 years old in the hearing aid repair department. In his time with the there, he worked in nearly every corner of the business. Named President of Starkey in 2017 and CEO in 2020, Sawalich now leads a global team of over 5,000 people.

Most recently, Starkey launched Genesis AI—the most recent addition of hearing technology in the company’s portfolio. The fitting software, Pro Fit, was designed based on input from hearing professionals around the globe.

Source: Starkey
Image credit: Starkey

04/14/2023

14th Annual Davis Lecture Takes Place April 14

Expert of hearing history set to present at the 14th annual Richard B. Davis MD, PhD, History of Medicine Lecture held at UNMC

Jaipreet Virdi, PhD, assistant professor in the Department of History at the University of Delaware, is presenting at the 14th annual Richard B. Davis, MD, PhD, History of Medicine Lecture on April 14 from noon to 1 p.m. ET.

The lecture, titled “Negotiating Normalcy: Deafness Cures in American History,” will be a hybrid event located at the University of Nebraska Medical Center (UNMC) College of Public Health auditorium, room 3013, as well as on Zoom *(registration required). An American Sign Language interpreter will be present, and Zoom captioning will be available.

https://unmc.zoom.us/webinar/register/WN_cY5iN-V1Th2XZBBqP_OPzw

Virdi is an historian of medicine, technology and disability, and has focused her research on the ways medicine and technology impact people with disability. She is the author of Hearing Happiness: Deafness Cures in History, is co-editor of Disability and the Victorians: Attitudes, Legacies, Interventions, and has published articles on diagnostic technologies, audiometry and the medicalization of deafness.

Focusing on the marketing of cures for deafness—hearing trumpets, electrotherapy apparatuses, and hearing aids—Virdi’s presentation is centered on the ways deaf people sought to restore or gain hearing throughout history. The history, according to Virdi, provides a broad context for understanding the lived experiences of deaf people and how cultural pressures of normalcy significantly stigmatized deafness.

The library will hold a drawing for Virdi’s book, Hearing Happiness: Deafness Cures in History. Entries can be made online here:
https://forms.office.com/Pages/ResponsePage.aspx?id=QImihGS0w0G6O7T6ZmW8BXCu1duKeXNDrGGRK90ezEhUQkJTOVNLTVBFUVlMUlFBMk1MUjNRVkIyViQlQCN0PWcu

Boxed lunches will be available to the first 50 in-person attendees.

Source: Heather Brown, McGoogan Health Sciences Library, University of Nebraska Medical Center

Image: University of Nebraska Medical Center

04/13/2023

Experts Confirm Betahistine’s Clinical Utility in the Treatment of Benign Paroxysmal Positional Vertigo (BPPV)

Meta-analysis shows oral betahistine combined with Epley maneuver reduces dizziness in posterior canal BPPV patients.

Altamira Therapeutics, a company that develops RNA-based therapeutics, reports highlights from a peer reviewed article showing the efficacy of oral betahistine in the treatment of posterior canal benign paroxysmal positional vertigo (BPPV) when administered along with a canal repositioning procedure, the Epley maneuver.

The article was published in the journal Medicine and describes the results from a meta-analysis of nine randomized controlled trials with 860 posterior canal BPPV patients, of which 432 were treated with Epley’s maneuver plus betahistine, and 428 solely underwent Epley’s maneuver. According to the meta-analysis, Epley’s maneuver plus the use of betahistine resulted in a significantly greater reduction in dizziness handicap as measured by the Dizziness Handicap Inventory (DHI) compared to Epley’s maneuver alone (p = 0.001).

Betahistine is a small molecule structural analog of histamine and acts as an agonist at the H1 histamine receptor and as an antagonist at the H3 histamine receptor, report experts. Unlike histamine, it crosses the blood-brain-barrier. Betahistine is known to increase the release of histamine, acetylcholine, dopamine and norepinephrine in the brain. It increases cochlear, vestibular and cerebral blood flow and facilitates vestibular compensation and inhibits neuronal firing in the vestibular nuclei. Betahistine for oral administration is reportedly approved in about 115 countries (with the U.S. being a notable exception) for the treatment of vertigo and Meniere’s disease. Despite its good safety profile, the clinical utility of orally administered Betahistine is limited due to poor bioavailability.

Experts say that BPPV is characterized by repeated episodes of vertigo (dizziness) produced by changes in the head position relative to gravity, e.g. when tipping the head backward. It is typically caused by dislodged inner ear particles (otoconia) in one of the semicircular canals, most often the posterior canal. Reportedly, the debris elicits unwanted vestibular stimulation and is often cleared through physical repositioning procedures such as the Epley maneuver, which is strongly recommended by the Clinical Practice Guideline of the American Academy of Otolaryngology – Head and Neck Surgery. According to the academy, since a patient may experience dizziness and instability for some time even after a successful maneuver, betahistine as an antivertigo drug is frequently administered to help accelerate their resolution.

According to a study published in the journal Otolaryngology – Head and Neck Surgery, BPPV is the most common type of vertigo, which accounts for 17 to 42% of all diagnosed cases. A primary complaint of dizziness accounts for 5.6 million clinic visits in the United States per year. Experts say that patients, suffering from BPPV, experience significant inconveniences and disabilities during symptomatic episodes, as they interfere with day-to-day activities such as driving a car or climbing stairs;BPPV generally emerges in the elderly with a peak onset in the between 50-60 years of age.

Altamira has been developing AM-125, a patented formulation of betahistine for intranasal administration, for the treatment of acute vestibular syndrome (AVS), which may be triggered by a variety of causes including trauma, infection or inner ear fluid disturbances such as in BPPV. The company states that by avoiding the fast metabolism after oral intake, intranasal delivery of AM-125 achieves higher bioavailability of betahistine (5-to-29 times higher). AM-125 has been reportedly tested in a Phase 2 clinical trial (“TRAVERS”) with patients suffering from AVS following vestibular surgery. Researchers noted that compared to placebo, AM-125 treatment helped accelerate vestibular compensation and alleviate signs and symptoms of vestibular dysfunction. The Company expects to file an IND application for intranasal betahistine (AM-125) with the FDA in May 2023, including the protocol for its Phase 2 clinical trial in BPPV.

“We are pleased to see betahistine’s clinical utility further confirmed in this meta-analysis of several studies in BPPV patients,” commented Thomas Meyer, PhD, Altamira’s founder, chairman and CEO. “Following the positive outcomes in surgery-induced AVS in the TRAVERS trial, we feel vindicated in our choice of BPPV to advance the clinical development program for AM-125. Where marketed, BPPV has traditionally been one of the most frequent indications for oral betahistine. We look forward to submitting the IND application shortly which will be an important milestone on our way to transfer the innovative AM-125 program to one or several partners as we are repositioning the Company around our RNA delivery technology.”

For more information about Altamira, visit the company website.
https://altamiratherapeutics.com/

Source: Altamira
Image Credit: ©Andrey Popov, Dreamstime

A Atlantic Hearing Aid Center

04/24/2023

04/21/2023

04/20/2023

04/19/2023

04/18/2023

04/17/2023

04/14/2023

04/13/2023

Address

Opening Hours

Website

Alerts

Shortcuts

Share

Category

Monday	8am - 4pm
Tuesday	8am - 4pm
Wednesday	8am - 4pm
Thursday	8am - 4pm
Friday	8am - 2pm